Abbott heart drug shows scant benefit-study
Posted on: Wednesday, 16 November 2005, 09:28 CST
DALLAS (Reuters) - Abbott Laboratories Inc.'s experimental heart failure drug Simdax failed to significantly improve survival over the current standard treatment for the sickest patients after 180 days, according to a new study presented on Wednesday.
The drug showed early benefit in reducing death in the 1,327-patient study comparing Simdax to dobutamine. But Abbott's drug did not meet the main goal of reducing death by 25 percent after six months, researchers who presented the data said at the American Heart Association annual scientific meeting in Dallas.
Source: REUTERS
Related Articles
- The Drug Information Center Arthritis Project: Providing Patients With Interactive and Reliable Arthritis Internet Education
- WHO Programme for International Drug Monitoring
- Abnormal Drug Response: Opportunities for Risk Reduction Through Pharmacogenetics
- Advances in Single-Patient Trials for Drug Treatment Optimization and Risk Management*
- 12 Freed for Texas Drug Bust Appeals
- 12 Freed in Appeal of Texas Drug Busts
- 'Rapid Detox' Breaks Drug Habits Quickly
- Advisers: Arthritis Drug Not Too Risky
- 55 Charged With Selling Drug Gear Online
- ADHD Drug Prescriptions Vary by ZIP Code
Rating: 2.2 / 5 (9 votes)
 |
 |
Rate this article:
User Comments (0)
RSS Feeds